• market

  STOCKS

• ipo date

  May 27, 2021

MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. The company is headquartered in Kelowna, Canada.

*Estimate based on analyst consensus